Liu Xuehua, Zhang Xueru, Li Qing, Tian Zhuomin
Department of Infection and Immunity, Tianjin People's Hospital, Tianjin 300121, China, Corresponding author: Li Qing, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014 Sep;26(9):655-60. doi: 10.3760/cma.j.issn.2095-4352.2014.09.010.
To evaluate the significance of the mannose-binding lection (MBL) gene polymorphism at code 54 of exon1 and MBL serum level and C-reactive protein (CRP) in the severity of community acquired pneumonia (CAP) in adults.
A prospective observation was conducted. 104 adults Han patients with CAP hospitalized in Tianjin People's Hospital were enrolled. Frequencies of MBL54 alleles and genotypes were measured. The patients were evaluated by pneumonia severity index (PSI) score and were graded. Serum MBL was determined by enzyme linked immunosorbent assay (ELISA), and serum CRP was detected by immunoturbidimetry before and 4 days and 7 days after the treatment. 100 healthy control subjects with the same region, age, gender, nationality were enrolled as control group. Serum MBL and CRP levels were compared between CAP group and the control group or among different grades of PSI, and the correlation was analyzed.
The variation of GGC->GGC in MBL54 was found in CAP patients and controls. Similar frequencies of genotypes (χ² = 0.018, P=0.893) and alleles (χ² = 0.019, P=0.903) of MBL54 with wild type and mutant type were found between two groups. The serum MBL level (mg/L) before and 4 days and 7 days after the treatment in CAP group was increased followed by the reduction and they were 3.75 ± 1.78, 4.53 ± 1.99 and 4.04 ± 1.91, respectively, which were significantly higher than those in control group (2.84 ± 1.41, all P<0.01). The serum CRP levels (mg/L) in CAP group were gradually declined, and they were 66.88 ± 40.47, 51.21 ± 37.54, 36.91 ± 36.02, respectively, which were significantly higher than those in control group (6.96 ± 2.19, all P<0.01). There were 12 cases with PSI grade I, 32 cases with grade II, 20 cases with grade III, 22 cases with grade IV and 18 cases with grade V in CAP patients. There was no significant difference in frequencies of MBL54 genotypes among different grades of PSI (χ² = 1.210, P=0.876) and between general ward and intensive care unit (χ² = 0.569, P=0.451). No differences in the serum MBL level before (F=1.313, P=0.279) and 4 days (F=1.705, P=0.165) and 7 days (F=1.684, P=0.170) after the treatment were found among different PSI grades. The serum MBL level 4 days after the treatment was significantly higher than that before treatment, then decreased to the level before treatment on the 7th day after treatment in CAP patients with grade II-IV. There was significant difference in serum CRP level before (F=23.179, P=0.000) and 4 days (F=26.601, P=0.000) and 7 days (F=10.358, P=0.000) after the treatment among different PSI grades in CAP patients. The serum levels of CRP in patients with different PSI grades were gradually decreased with time prolonged, the higher the PSI grade, the more obscure the serum CRP decrease. No correlation was found between PSI grade and serum MBL before and 4 days and 7 days after the treatment (before treatment: r=-0.205, P=0.145; 4 days after treatment: r=-0.062, P=0.662; 7 days after treatment: r=-0.063, P=0.656), and positive correlation between PSI grade and serum CRP was found(before treatment: r=0.809, P=0.000; 4 days after treatment: r=0.842, P=0.000; 7 days after treatment: r=0.702, P=0.000).
The MBL54 codon genotypes had no effect on the susceptibility of CAP. The serum MBL was elevated and dynamic changes with increasing treatment time in CAP patients were shown. MBL can be used as a reaction of CAP in acute stage. But it cannot be used as an inflammatory marker for the severity of CAP.
评估外显子1第54位密码子的甘露糖结合凝集素(MBL)基因多态性、MBL血清水平及C反应蛋白(CRP)在成人社区获得性肺炎(CAP)严重程度中的意义。
进行前瞻性观察。纳入天津市人民医院收治的104例成年汉族CAP患者。检测MBL54等位基因和基因型频率。采用肺炎严重指数(PSI)评分对患者进行评估并分级。治疗前、治疗后4天和7天,采用酶联免疫吸附测定(ELISA)法测定血清MBL,采用免疫比浊法检测血清CRP。选取100例来自同一地区、年龄、性别、民族的健康对照者作为对照组。比较CAP组与对照组之间或不同PSI分级之间的血清MBL和CRP水平,并分析其相关性。
在CAP患者和对照组中均发现MBL54的GGC->GGC变异。两组间MBL54野生型和突变型的基因型频率(χ² = 0.018,P = 0.893)和等位基因频率(χ² = 0.019,P = 0.903)相似。CAP组治疗前、治疗后4天和7天的血清MBL水平(mg/L)先升高后降低,分别为3.75±1.78、4.53±1.99和4.04±1.91,均显著高于对照组(2.84±1.41,P均<0.01)。CAP组血清CRP水平(mg/L)逐渐下降,分别为66.88±40.47、51.21±37.54、36.91±36.02,均显著高于对照组(6.96±2.19,P均<0.01)。CAP患者中,PSIⅠ级12例,Ⅱ级32例,Ⅲ级20例,Ⅳ级22例,Ⅴ级18例。不同PSI分级间MBL54基因型频率差异无统计学意义(χ² = 1.210,P = 0.876),普通病房与重症监护病房间差异无统计学意义(χ² = 0.569,P = 0.451)。不同PSI分级患者治疗前(F = 1.313,P = 0.279)、治疗后4天(F = 1.705,P = 0.165)和7天(F = 1.684,P = 0.170)的血清MBL水平差异无统计学意义。Ⅱ-Ⅳ级CAP患者治疗后4天血清MBL水平显著高于治疗前,治疗后7天降至治疗前水平。不同PSI分级CAP患者治疗前(F = 23.179,P = 0.000)、治疗后4天(F = 26.601,P = 0.000)和7天(F = 10.358,P = 0.000)的血清CRP水平差异有统计学意义。不同PSI分级患者的血清CRP水平随时间延长逐渐降低,PSI分级越高,血清CRP下降越不明显。治疗前、治疗后4天和7天,PSI分级与血清MBL无相关性(治疗前:r = -0.205,P = 0.145;治疗后4天:r = -0.062,P = 0.662;治疗后7天:r = -0.063,P = 0.656),而PSI分级与血清CRP呈正相关(治疗前:r = 0.809,P = 0.000;治疗后4天:r = 0.842,P = 0.000;治疗后7天:r = 0.702,P = 0.000)。
MBL54密码子基因型对CAP易感性无影响。CAP患者血清MBL升高且随治疗时间延长呈动态变化。MBL可作为CAP急性期的反应指标,但不能作为CAP严重程度的炎症标志物。